Selected research
Industry Growth & Trends
Global Oncology Biosimilars Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Oncology Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Oncology Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Oncology Biosimilars market include Teva Pharmaceutical Industries Ltd, Sandoz International, Pfizer, STADA Arzneimittel AG, Intas Pharmaceuticals, Dr. Reddy’s Laboratories, Celltrion, Biocon and BIOCAD, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Oncology Biosimilars market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Oncology Biosimilars market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oncology Biosimilars market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oncology Biosimilars.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Oncology Biosimilars market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Oncology Biosimilars Market by Company
Teva Pharmaceutical Industries Ltd
Sandoz International
Pfizer
STADA Arzneimittel AG
Intas Pharmaceuticals
Dr. Reddy’s Laboratories
Celltrion
Biocon
BIOCAD
Apotex
Oncology Biosimilars Segment by Type
Hematopoietic Agents
Monoclonal Antibody
G-CSF
Others
Oncology Biosimilars Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacies
Oncology Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Oncology Biosimilars companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Hematopoietic Agents
- Monoclonal Antibody
- G-CSF
- Others
Applications
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacies
Companies covered
- Teva Pharmaceutical Industries Ltd
- Sandoz International
- Pfizer
- STADA Arzneimittel AG
- Intas Pharmaceuticals
- Dr. Reddy’s Laboratories
- Celltrion
- Biocon
- BIOCAD
- Apotex
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Oncology Biosimilars Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Oncology Biosimilars Market Size by Region (2021-2032)
- 1.4.1 Global Oncology Biosimilars Market Size by Region (2021-2026)
- 1.4.2 Global Oncology Biosimilars Market Size by Region (2027-2032)
- 1.5 Key Regions Oncology Biosimilars Market Size (2021-2032)
- 1.5.1 North America Oncology Biosimilars Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Oncology Biosimilars Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Oncology Biosimilars Market Size Growth Rate (2021-2032)
- 1.5.4 South America Oncology Biosimilars Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Oncology Biosimilars Market Size Growth Rate (2021-2032)
2 Oncology Biosimilars Market by Type
- 2.1 Type Introduction
- 2.1.1 Hematopoietic Agents
- 2.1.2 Monoclonal Antibody
- 2.1.3 G-CSF
- 2.1.4 Others
- 2.2 Global Oncology Biosimilars Market Size by Type
- 2.2.1 Global Oncology Biosimilars Market Size Overview by Type (2021-2032)
- 2.2.2 Global Oncology Biosimilars Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Oncology Biosimilars Market Size Forecasted by Type (2027-2032)
- 2.3 Global Oncology Biosimilars Market Size by Regions
- 2.3.1 North America Oncology Biosimilars Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Oncology Biosimilars Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Oncology Biosimilars Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Oncology Biosimilars Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Oncology Biosimilars Market Size Breakdown by Type (2021-2026)
3 Oncology Biosimilars Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital Pharmacy
- 3.1.2 Online Pharmacy
- 3.1.3 Retail Pharmacies
- 3.2 Global Oncology Biosimilars Market Size by Application
- 3.2.1 Global Oncology Biosimilars Market Size Overview by Application (2021-2032)
- 3.2.2 Global Oncology Biosimilars Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Oncology Biosimilars Market Size Forecasted by Application (2027-2032)
- 3.3 Global Oncology Biosimilars Market Size by Regions
- 3.3.1 North America Oncology Biosimilars Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Oncology Biosimilars Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Oncology Biosimilars Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Oncology Biosimilars Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Oncology Biosimilars Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Oncology Biosimilars Industry Trends
- 4.2 Oncology Biosimilars Industry Drivers
- 4.3 Oncology Biosimilars Industry Opportunities and Challenges
- 4.4 Oncology Biosimilars Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Oncology Biosimilars Revenue (2021-2026)
- 5.2 Global Oncology Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Oncology Biosimilars Key Company Headquarters & Area Served
- 5.4 Global Oncology Biosimilars Company, Product Type & Application
- 5.5 Global Oncology Biosimilars Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Oncology Biosimilars Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Oncology Biosimilars Players Market Share by Revenue in 2025
- 5.6.3 2025 Oncology Biosimilars Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Teva Pharmaceutical Industries Ltd
- 6.1.1 Teva Pharmaceutical Industries Ltd Company Information
- 6.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 6.1.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio
- 6.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 6.2 Sandoz International
- 6.2.1 Sandoz International Company Information
- 6.2.2 Sandoz International Business Overview
- 6.2.3 Sandoz International Oncology Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Sandoz International Oncology Biosimilars Product Portfolio
- 6.2.5 Sandoz International Recent Developments
- 6.3 Pfizer
- 6.3.1 Pfizer Company Information
- 6.3.2 Pfizer Business Overview
- 6.3.3 Pfizer Oncology Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Pfizer Oncology Biosimilars Product Portfolio
- 6.3.5 Pfizer Recent Developments
- 6.4 STADA Arzneimittel AG
- 6.4.1 STADA Arzneimittel AG Company Information
- 6.4.2 STADA Arzneimittel AG Business Overview
- 6.4.3 STADA Arzneimittel AG Oncology Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 STADA Arzneimittel AG Oncology Biosimilars Product Portfolio
- 6.4.5 STADA Arzneimittel AG Recent Developments
- 6.5 Intas Pharmaceuticals
- 6.5.1 Intas Pharmaceuticals Company Information
- 6.5.2 Intas Pharmaceuticals Business Overview
- 6.5.3 Intas Pharmaceuticals Oncology Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Intas Pharmaceuticals Oncology Biosimilars Product Portfolio
- 6.5.5 Intas Pharmaceuticals Recent Developments
- 6.6 Dr. Reddy’s Laboratories
- 6.6.1 Dr. Reddy’s Laboratories Company Information
- 6.6.2 Dr. Reddy’s Laboratories Business Overview
- 6.6.3 Dr. Reddy’s Laboratories Oncology Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Dr. Reddy’s Laboratories Oncology Biosimilars Product Portfolio
- 6.6.5 Dr. Reddy’s Laboratories Recent Developments
- 6.7 Celltrion
- 6.7.1 Celltrion Company Information
- 6.7.2 Celltrion Business Overview
- 6.7.3 Celltrion Oncology Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Celltrion Oncology Biosimilars Product Portfolio
- 6.7.5 Celltrion Recent Developments
- 6.8 Biocon
- 6.8.1 Biocon Company Information
- 6.8.2 Biocon Business Overview
- 6.8.3 Biocon Oncology Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Biocon Oncology Biosimilars Product Portfolio
- 6.8.5 Biocon Recent Developments
- 6.9 BIOCAD
- 6.9.1 BIOCAD Company Information
- 6.9.2 BIOCAD Business Overview
- 6.9.3 BIOCAD Oncology Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 BIOCAD Oncology Biosimilars Product Portfolio
- 6.9.5 BIOCAD Recent Developments
- 6.10 Apotex
- 6.10.1 Apotex Company Information
- 6.10.2 Apotex Business Overview
- 6.10.3 Apotex Oncology Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Apotex Oncology Biosimilars Product Portfolio
- 6.10.5 Apotex Recent Developments
7 North America
- 7.1 North America Oncology Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Oncology Biosimilars Market Size by Country (2021-2026)
- 7.3 North America Oncology Biosimilars Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Oncology Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Oncology Biosimilars Market Size by Country (2021-2026)
- 8.3 Europe Oncology Biosimilars Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Oncology Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Oncology Biosimilars Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Oncology Biosimilars Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Oncology Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Oncology Biosimilars Market Size by Country (2021-2026)
- 10.3 South America Oncology Biosimilars Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Oncology Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Oncology Biosimilars Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Oncology Biosimilars Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst